<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2023-2-50-56</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-1409</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Сравнение реологических и вязкоупругих свойств медицинских изделий гиалуроновой кислоты для внутрисуставного введения</article-title><trans-title-group xml:lang="en"><trans-title>Comparison of rheological and viscoelastic properties of hyaluronic acid for intraarticular injections</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3092-9753</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Призов</surname><given-names>А. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Prizov</surname><given-names>A. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алексей Петрович Призов</p><p>117198, Москва, ул. Миклухо-Маклая, 6</p></bio><bio xml:lang="en"><p>Alexey Petrovich Prizov</p><p>6, Miklukho-Maclay Street, Moscow 117198</p></bio><email xlink:type="simple">aprizov@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6736-9772</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Загородний</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zagorodniy</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>117198, Москва, ул. Миклухо-Маклая, 6</p></bio><bio xml:lang="en"><p>6, Miklukho-Maclay Street, Moscow 117198</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5292-7930</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лазко</surname><given-names>Ф. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Lazko</surname><given-names>F. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>117198, Москва, ул. Миклухо-Маклая, 6</p></bio><bio xml:lang="en"><p>6, Miklukho-Maclay Street, Moscow 117198</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6335-1997</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Никитин</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikitin</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>117198, Москва, ул. Миклухо-Маклая, 6</p></bio><bio xml:lang="en"><p>6, Miklukho-Maclay Street, Moscow 117198</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2542-8308</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Беляк</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Belyak</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>117198, Москва, ул. Миклухо-Маклая, 6</p></bio><bio xml:lang="en"><p>6, Miklukho-Maclay Street, Moscow 117198</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6346-824X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лазко</surname><given-names>М. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Lazko</surname><given-names>M. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>117198, Москва, ул. Миклухо-Маклая, 6</p></bio><bio xml:lang="en"><p>6, Miklukho-Maclay Street, Moscow 117198</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6667-5006</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каменчук</surname><given-names>Я. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kamenchuk</surname><given-names>Ya. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>195279, Санкт-Петербург, Индустриальный проспект, 71, стр. 2А</p></bio><bio xml:lang="en"><p>71,Industrial Prospect, Build. 2A, Saint Petersburg 195279</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8573-063X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ильина</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Il’ina</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>195279, Санкт-Петербург, Индустриальный проспект, 71, стр. 2А</p></bio><bio xml:lang="en"><p>71,Industrial Prospect, Build. 2A, Saint Petersburg 195279</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Российский университет дружбы народов»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>RUDN University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ООО «Гротекс»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Grotex LLC</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>22</day><month>04</month><year>2023</year></pub-date><volume>17</volume><issue>2</issue><fpage>50</fpage><lpage>56</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Призов А.П., Загородний Н.В., Лазко Ф.Л., Никитин А.А., Беляк Е.А., Лазко М.Ф., Каменчук Я.А., Ильина Е.А., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Призов А.П., Загородний Н.В., Лазко Ф.Л., Никитин А.А., Беляк Е.А., Лазко М.Ф., Каменчук Я.А., Ильина Е.А.</copyright-holder><copyright-holder xml:lang="en">Prizov A.P., Zagorodniy N.V., Lazko F.L., Nikitin A.A., Belyak E.A., Lazko M.F., Kamenchuk Y.A., Il’ina E.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/1409">https://mrj.ima-press.net/mrj/article/view/1409</self-uri><abstract><p>Остеоартрит (ОА) – наиболее распространенное заболевание суставов, которое поражает более 80% лиц старше 55 лет и на последних стадиях приводит к инвалидности. Одним из безопасных неоперативных методов лечения ОА является использование внутрисуставных инъекции медицинских изделий гиалуроновои кислоты (ГлК).</p><p>Цель исследования – сравнение вязкоупругих реологических свойств медицинских изделий ГлК с различной концентрацией гиалуроната натрия (ГН), доступных для использования в Российской Федерации.</p><sec><title>Материал и методы</title><p>Материал и методы. Исследование проводилось с помощью модульного реометра MCR 302 (Anton Paar, Австрия). Все измерения выполнялись при температуре 25,0±0,1 °С с использованием измерительной системы «конус-плоскость» (угол – 2°, диаметр конуса – 40 мм, высота зазора – 0,169 мм). Определение модулей упругости (G’) и вязкости (G”) осуществляли в зависимости от частоты в линейной области напряжения сдвига, а динамической вязкости – при скорости сдвига 1 с-1.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Оценка реологических свойств исследуемых образцов выявила положительную связь с концентрацией ГН и отсутствие связи с молекулярной массой ГН. Самыми высокими вязкоупругими свойствами обладали медицинские изделия в группе с концентрацией ГН 1%: Армавискон и Рипарт; в группе с концентрацией ГН 1,5–1,6% все исследуемые образцы, кроме Хиалубрикса, показали схожие, более высокие по сравнению с предыдущей группой, результаты; в группе с концентрацией ГН 2–3% наиболее высокие показатели имел Армавискон Платинум и несколько меньшие – Флексотрон Ультра и Армавискон Форте.</p></sec><sec><title>Заключение</title><p>Заключение. Изучение реологических вязкоупругих свойств медицинских изделий ГлК является наиболее доступным методом, на основании которого можно прогнозировать клинический эффект.</p></sec></abstract><trans-abstract xml:lang="en"><p>Osteoarthritis (OA) is the most common joint disease that affects more than 80% of people over 55 years and in its final stages leads to disability. One of the safe non-surgical methods of OA treatment is intra-articular injections of hyaluronic acid (HA).</p><sec><title>Objective</title><p>Objective: to compare the viscoelastic rheological properties of HA medical products with different concentrations of sodium hyaluronate (SH) available in the Russian Federation.</p></sec><sec><title>Material and methods</title><p>Material and methods. The study was carried out using a modular rheometer MCR 302 (Anton Paar, Austria). All measurements were carried out at a temperature of 25.0±0.1 °C using the measuring system "cone-plane" (angle – 2 ˚ , cone diameter – 40 mm, gap height – 0.169 mm). The determination of the elastic moduli (G’) and viscosity (G”) was carried out depending on the frequency in the linear region of the shear stress, and the dynamic viscosity was determined at a shear rate of 1 sec-1.</p></sec><sec><title>Results</title><p>Results. The evaluation of the rheological properties of the studied samples revealed a positive relationship with the concentration of SH and no relationship with the molecular weight of SH. The highest viscoelastic properties were possessed by medical products in the 1% SH group: Armaviscon and Ripart; in the group with SH concentration of 1.5–1.6%, all the studied samples, except for Hyalubrix, showed similar higher results compared to the previous group; in the group with SH concentration of 2–3%, Armaviscon Platinum had the highest results and Flexotron Ultra and Armaviscon Forte – somewhat lower results.</p></sec><sec><title>Conclusion</title><p>Conclusion. The study of the rheological viscoelastic properties of HA medical products is the most accessible method, on the basis of which it is possible to predict the clinical effect.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>остеоартрит</kwd><kwd>гиалуроновая кислота</kwd><kwd>гиалуронат натрия</kwd><kwd>реологические свойства</kwd><kwd>внутрисуставные инъекции</kwd></kwd-group><kwd-group xml:lang="en"><kwd>osteoarthritis</kwd><kwd>hyaluronic acid</kwd><kwd>sodium hyaluronate</kwd><kwd>rheological properties</kwd><kwd>intraarticular injections</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Насонов ЕЛ, Насонова ВА, редакторы. Ревматология. Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. С. 573-88.</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Nasonov EL, Nasonova VA, editors. Revmatologiya. Natsional'noe rukovodstvo [Rheumatology. National Guide]. Moscow: GEOTAR-media; 2008. P. 573-88.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Osteoarthritis Research Society International. Osteoarthritis: a serious disease, submitted to the US Food and Drug Administration. https://oarsi.org/sites/default/files/docs/2016/oarsi_white_paper_oa_serious_disease_121416_1.pdf</mixed-citation><mixed-citation xml:lang="en">Osteoarthritis Research Society International. Osteoarthritis: a serious disease, submitted to the US Food and Drug Administration. https://oarsi.org/sites/default/files/docs/2016/oarsi_white_paper_oa_serious_disease_121416_1.pdf</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008 Jan; 58(1):26-35. doi: 10.1002/art.23176.</mixed-citation><mixed-citation xml:lang="en">Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008 Jan; 58(1):26-35. doi: 10.1002/art.23176.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disabilityadjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1859-922. doi: 10.1016/S0140-6736(18)32335-3.</mixed-citation><mixed-citation xml:lang="en">GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disabilityadjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1859-922. doi: 10.1016/S0140-6736(18)32335-3.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Мартусевич НА. Остеоартроз. Вопросы эпидемиологии, этиопатогенеза, клиники, диагностики и лечения. Методические рекомендации. БГМУ; 2003. 28 с.</mixed-citation><mixed-citation xml:lang="en">Martusevich NA. Voprosy epidemiologii, etiopatogeneza, kliniki, diagnostiki i lecheniya. Metodicheskie rekomendatsii [Osteoarthritis. Issues of epidemiology, etiopathogenesis, clinic, diagnosis and treatment. Methodological recommendations]. BGMU; 2003. 28 p.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Huskisson EC. Nimesulide, a balanced drug for treatment for treatment of osteoarthrosis. Clin Exp Rheumatol. 2001;19 (1 Suppl 22):S21-5.</mixed-citation><mixed-citation xml:lang="en">Huskisson EC. Nimesulide, a balanced drug for treatment for treatment of osteoarthrosis. Clin Exp Rheumatol. 2001;19 (1 Suppl 22):S21-5.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Алексеева ЛИ, Лила АМ. Базисная терапия остеоартрита: современный взгляд на применение препаратов глюкозамина и хондроитина. Современная ревматология. 2021;15(2):112-9. doi: 10.14412/1996-7012-2021-2-112-119</mixed-citation><mixed-citation xml:lang="en">Alekseeva LI, Lila AM. Osteoarthritis background therapy: current view on the glucosamine and chondroitin therapy. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2021;15(2):112-9. (In Russ.). doi: 10.14412/1996-7012-2021-2-112-119</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Стребкова ЕА, Алексеева ЛИ. Остеоартроз и ожирение. Научно-практическая ревматология. 2015;53(5):542–52.</mixed-citation><mixed-citation xml:lang="en">Strebkova EA, Alekseeva LI. Osteoarthritis and obesity. Nauchno-prakticheskaya revmatologiya. 2015;53(5):542–52. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Wieland HA, Michaelis M, Kirschbaum BJ, Rudolphi KA. Osteoarthritis — an untreatable disease? Nat Rev Drug Discov. 2005 Apr; 4(4):331-44. doi: 10.1038/nrd1693.</mixed-citation><mixed-citation xml:lang="en">Wieland HA, Michaelis M, Kirschbaum BJ, Rudolphi KA. Osteoarthritis — an untreatable disease? Nat Rev Drug Discov. 2005 Apr; 4(4):331-44. doi: 10.1038/nrd1693.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Лила АМ, Алексеева ЛИ, Бабаева АР и др. Возможности фармакологического лечения остеоартрита: фокус на симптоматические медленно действующие препараты (SYSADOA) и индивидуальные особенности пациента. Резолюция международного совещания экспертов. Современная ревматология. 2019;13(4):143-7. doi: 10.14412/1996-7012-2019-4-143-147</mixed-citation><mixed-citation xml:lang="en">Lila AM, Alekseeva LI, Babaeva AR, et al. Pharmacological treatment options for osteoarthritis: focus on symptomatic slow-acting drugs for osteoarthritis (SYSADOA) and individual patient characteristics: Resolution of the International Expert Meeting. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(4):143-7. (In Russ.). doi: 10.14412/1996-7012-2019-4-143-147</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Scarpignato C, Lanas A, Blandizzi C, et al. Safe prescribing of non-steroidal antiinflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015 Mar 19;13:55. doi: 10.1186/s12916-015-0285-8.</mixed-citation><mixed-citation xml:lang="en">Scarpignato C, Lanas A, Blandizzi C, et al. Safe prescribing of non-steroidal antiinflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015 Mar 19;13:55. doi: 10.1186/s12916-015-0285-8.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Honvo G, Reginster JY, Rannou F, et al. Safety of intra-articular hyaluronic acid injections in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019 Apr;36(Suppl 1):101-27. doi: 10.1007/s40266-019-00657-w.</mixed-citation><mixed-citation xml:lang="en">Honvo G, Reginster JY, Rannou F, et al. Safety of intra-articular hyaluronic acid injections in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019 Apr;36(Suppl 1):101-27. doi: 10.1007/s40266-019-00657-w.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Hyaluronan or hylans for knee osteoarthritis? Drug Ther Bull. 1999 Sep;37(9):71-2. doi: 10.1136/dtb.1999.37971.</mixed-citation><mixed-citation xml:lang="en">Hyaluronan or hylans for knee osteoarthritis? Drug Ther Bull. 1999 Sep;37(9):71-2. doi: 10.1136/dtb.1999.37971.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Waller KA, Zhang LX, Fleming BC, Jay GD. Preventing friction-induced chondrocyte apoptosis: comparison of human synovial fluid and hylan G-F 20. J Rheumatol. 2012 Jul;39(7):1473-80. doi: 10.3899/jrheum.111427. Epub 2012 Jun 1.</mixed-citation><mixed-citation xml:lang="en">Waller KA, Zhang LX, Fleming BC, Jay GD. Preventing friction-induced chondrocyte apoptosis: comparison of human synovial fluid and hylan G-F 20. J Rheumatol. 2012 Jul;39(7):1473-80. doi: 10.3899/jrheum.111427. Epub 2012 Jun 1.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Agerup B, Berg P, Akermark C. Non-animal stabilized hyaluronic acid: a new formulation for the treatment of osteoarthritis. BioDrugs. 2005;19(1):23-30. doi: 10.2165/00063030-200519010-00003.</mixed-citation><mixed-citation xml:lang="en">Agerup B, Berg P, Akermark C. Non-animal stabilized hyaluronic acid: a new formulation for the treatment of osteoarthritis. BioDrugs. 2005;19(1):23-30. doi: 10.2165/00063030-200519010-00003.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Band PA, Heeter J, Wisniewski HG, et al. Hyaluronan molecular weight distribution is associated with the risk of knee osteoarthritis progression. Int J Stroke. 2018 Aug;13(6): 612-32. doi: 10.1177/1747493018778713. Epub 2018 May 22.</mixed-citation><mixed-citation xml:lang="en">Band PA, Heeter J, Wisniewski HG, et al. Hyaluronan molecular weight distribution is associated with the risk of knee osteoarthritis progression. Int J Stroke. 2018 Aug;13(6): 612-32. doi: 10.1177/1747493018778713. Epub 2018 May 22.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Phillips M, Vannabouathong C, Devji T, et al. Differentiating factors of intra-articular injectables have a meaningful impact on knee osteoarthritis outcomes: a network metaanalysis. Knee Surg Sports Traumatol Arthrosc. 2020 Sep;28(9):3031-9. doi: 10.1007/s00167019-05763-1. Epub 2020 Jan 3.</mixed-citation><mixed-citation xml:lang="en">Phillips M, Vannabouathong C, Devji T, et al. Differentiating factors of intra-articular injectables have a meaningful impact on knee osteoarthritis outcomes: a network metaanalysis. Knee Surg Sports Traumatol Arthrosc. 2020 Sep;28(9):3031-9. doi: 10.1007/s00167019-05763-1. Epub 2020 Jan 3.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Altman RD, Bedi A, Karlsson J, et al. Product differences in intra-articular hyaluronic acids for osteoarthritis of the knee. Am J Sports Med. 2016 Aug;44(8):2158-65. doi: 10.1177/0363546515609599. Epub 2015 Nov 17.</mixed-citation><mixed-citation xml:lang="en">Altman RD, Bedi A, Karlsson J, et al. Product differences in intra-articular hyaluronic acids for osteoarthritis of the knee. Am J Sports Med. 2016 Aug;44(8):2158-65. doi: 10.1177/0363546515609599. Epub 2015 Nov 17.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta RC, Lall R, Srivastava A, Sinha A. Hyaluronic acid: molecular mechanisms and therapeutic trajectory. Front Vet Sci. 2019 Jun 25;6:192. doi: 10.3389/fvets.2019.00192. eCollection 2019.</mixed-citation><mixed-citation xml:lang="en">Gupta RC, Lall R, Srivastava A, Sinha A. Hyaluronic acid: molecular mechanisms and therapeutic trajectory. Front Vet Sci. 2019 Jun 25;6:192. doi: 10.3389/fvets.2019.00192. eCollection 2019.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Garantziotis S, Savani RC. Hyaluronan biology: a complex balancing act of structure, function, location and context. Matrix Biol. 2019 May;78-79:1-10. doi: 10.1016/j.matbio.2019.02.002. Epub 2019 Feb 23.</mixed-citation><mixed-citation xml:lang="en">Garantziotis S, Savani RC. Hyaluronan biology: a complex balancing act of structure, function, location and context. Matrix Biol. 2019 May;78-79:1-10. doi: 10.1016/j.matbio.2019.02.002. Epub 2019 Feb 23.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Rayahin JE, Buhrman JS, Zhang Y, et al. High and low molecular weight hyaluronic acid differentially influence macrophage activation. ACS Biomater Sci Eng. 2015 Jul 13; 1(7):481-93. doi: 10.1021/acsbiomaterials.5b00181.</mixed-citation><mixed-citation xml:lang="en">Rayahin JE, Buhrman JS, Zhang Y, et al. High and low molecular weight hyaluronic acid differentially influence macrophage activation. ACS Biomater Sci Eng. 2015 Jul 13; 1(7):481-93. doi: 10.1021/acsbiomaterials.5b00181.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Hashizume M, Mihara M. High molecular weight hyaluronic acid inhibits IL-6-induced MMP production from human chondrocytes by up-regulating the ERK inhibitor, MKP-1. Biochem Biophys Res Commun. 2010 Dec 10;403(2):184-9. doi: 10.1016/j.bbrc.2010.10.135. Epub 2010 Nov 6.</mixed-citation><mixed-citation xml:lang="en">Hashizume M, Mihara M. High molecular weight hyaluronic acid inhibits IL-6-induced MMP production from human chondrocytes by up-regulating the ERK inhibitor, MKP-1. Biochem Biophys Res Commun. 2010 Dec 10;403(2):184-9. doi: 10.1016/j.bbrc.2010.10.135. Epub 2010 Nov 6.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Хабаров ВН, Бойков ПЯ, Селянин МА. Гиалуроновая кислота. Москва: Практическая медицина; 2012. 224 c. [Khabarov VN, Boikov PYa, Selyanin MA Gialuronovaya kislota</mixed-citation><mixed-citation xml:lang="en">Khabarov VN, Boikov PYa, Selyanin MA Gialuronovaya kislota [Hyaluronic Acid]. Moscow: Prakticheskaya meditsina; 2012. 224 p.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Загородний НВ, Призов АП, Каменчук ЯА, Ильина ЕА. Реологические и вязкоупругие свойства препаратов гиалуроновой кислоты. Opinion Leader. 2021; (2):28-35.</mixed-citation><mixed-citation xml:lang="en">Zagorodnii NV, Prizov AP, Kamenchuk YaA, Il'ina EA. Rheological and viscoelastic properties of hyaluronic acid preparations. Opinion Leader. 2021;(2):28-35. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Liu C, Sun J. A porcine acellular dermal matrix induces human fibroblasts to secrete hyaluronic acid by activating JAK2/STAT3 signalling. RSC Adv. 2020 May 19;10(32): 18959-69. doi: 10.1039/c9ra03736e.</mixed-citation><mixed-citation xml:lang="en">Liu C, Sun J. A porcine acellular dermal matrix induces human fibroblasts to secrete hyaluronic acid by activating JAK2/STAT3 signalling. RSC Adv. 2020 May 19;10(32): 18959-69. doi: 10.1039/c9ra03736e.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Bauer C, Niculescu-Morzsa E, Jeyakumar V, et al. Chondroprotective effect of highmolecular-weight hyaluronic acid on osteoarthritic chondrocytes in a co-cultivation inflammation model with M1 macrophages. J Inflamm (Lond). 2016 Sep 13;13(1):31. doi: 10.1186/s12950-016-0139-y. eCollection 2016.</mixed-citation><mixed-citation xml:lang="en">Bauer C, Niculescu-Morzsa E, Jeyakumar V, et al. Chondroprotective effect of highmolecular-weight hyaluronic acid on osteoarthritic chondrocytes in a co-cultivation inflammation model with M1 macrophages. J Inflamm (Lond). 2016 Sep 13;13(1):31. doi: 10.1186/s12950-016-0139-y. eCollection 2016.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Waddell DD. Viscosupplementation with hyaluronans for osteoarthritis of the knee: clinical efficacy and economic implications. Drugs Aging. 2007;24(8):629-42. doi: 10.2165/00002512-200724080-00002.</mixed-citation><mixed-citation xml:lang="en">Waddell DD. Viscosupplementation with hyaluronans for osteoarthritis of the knee: clinical efficacy and economic implications. Drugs Aging. 2007;24(8):629-42. doi: 10.2165/00002512-200724080-00002.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Moreland LW. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis Res Ther. 2003;5(2):54-67. doi: 10.1186/ar623. Epub 2003 Jan 14.</mixed-citation><mixed-citation xml:lang="en">Moreland LW. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis Res Ther. 2003;5(2):54-67. doi: 10.1186/ar623. Epub 2003 Jan 14.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Ghosh P. The role of hyaluronic acid (hyaluronan) in health and disease: interactions with cells, cartilage and components of synovial fluid. Clin Exp Rheumatol. 1994 JanFeb;12(1):75-82.</mixed-citation><mixed-citation xml:lang="en">Ghosh P. The role of hyaluronic acid (hyaluronan) in health and disease: interactions with cells, cartilage and components of synovial fluid. Clin Exp Rheumatol. 1994 JanFeb;12(1):75-82.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">https://www.flottweg.com/ru/wiki/separation-technology/dynamic-viscosity</mixed-citation><mixed-citation xml:lang="en">https://www.flottweg.com/ru/wiki/separation-technology/dynamic-viscosity</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Snetkov P, Zakharova K, Morozkina S, et al. Hyaluronic Acid: The Influence of Molecular Weight on Structural, Physical, Physico-Chemical, and Degradable Properties of Biopolymer. Polymers (Basel). 2020 Aug 11; 12(8):1800. doi: 10.3390/polym12081800.</mixed-citation><mixed-citation xml:lang="en">Snetkov P, Zakharova K, Morozkina S, et al. Hyaluronic Acid: The Influence of Molecular Weight on Structural, Physical, Physico-Chemical, and Degradable Properties of Biopolymer. Polymers (Basel). 2020 Aug 11; 12(8):1800. doi: 10.3390/polym12081800.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Fagien S, Bertucci V, von Grote E, Mashburn JH. Rheologic and Physicochemical Properties Used to Differentiate Injectable Hyaluronic Acid Filler Products. Plast Reconstr Surg. 2019 Apr;143(4):707e-720e. doi: 10.1097/PRS.0000000000005429.</mixed-citation><mixed-citation xml:lang="en">Fagien S, Bertucci V, von Grote E, Mashburn JH. Rheologic and Physicochemical Properties Used to Differentiate Injectable Hyaluronic Acid Filler Products. Plast Reconstr Surg. 2019 Apr;143(4):707e-720e. doi: 10.1097/PRS.0000000000005429.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Nicholls M, Manjoo A, Shaw P, et al. A Comparison Between Rheological Properties of Intra-articular Hyaluronic Acid Preparations and Reported Human Synovial Fluid. Adv Ther. 2018 Apr;35(4):523-530. doi: 10.1007/s12325-018-0688-y. Epub 2018 Mar 14.</mixed-citation><mixed-citation xml:lang="en">Nicholls M, Manjoo A, Shaw P, et al. A Comparison Between Rheological Properties of Intra-articular Hyaluronic Acid Preparations and Reported Human Synovial Fluid. Adv Ther. 2018 Apr;35(4):523-530. doi: 10.1007/s12325-018-0688-y. Epub 2018 Mar 14.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Кавалерский ГМ, Кавалерский МГ, Дугина ЮЛ, Рукин ЯА. Сравнительная характеристика реологических свойств внутрисуставных протезов на основе гиалуроновой кислоты. Кафедра травматологии и ортопедии. 2018;(1):18-22.</mixed-citation><mixed-citation xml:lang="en">Kavalerskii GM, Kavalerskii MG, Dugina YuL, Rukin YaA. Comparative characteristics of rheological properties of intra-articular prostheses based on hyaluronic acid. Kafedra travmatologii i ortopedii. 2018;(1):18-22. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Blaine T, Moskowitz R, Udell J, et al. Treatment of persistent shoulder pain with sodium hyaluronate: a randomized, controlled trial. A multicenter study. J Bone Joint Surg Am. 2008 May;90(5):970-9. doi: 10.2106/JBJS.F.01116.</mixed-citation><mixed-citation xml:lang="en">Blaine T, Moskowitz R, Udell J, et al. Treatment of persistent shoulder pain with sodium hyaluronate: a randomized, controlled trial. A multicenter study. J Bone Joint Surg Am. 2008 May;90(5):970-9. doi: 10.2106/JBJS.F.01116.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
